Uncovering gaps in hepatitis B and C services for immigrants and newcomers: A new report from Action Hepatitis Canada

 May 22, 2024 •  By Jennifer van Gennip

Immigrants and newcomers make up almost a quarter of Canada’s population, contributing enormously to the social, cultural, and economic vitality of our country. To ensure Canada upholds its commitment to the well-being of newcomers and the strength of our diverse communities, it’s essential to prioritize equitable access to healthcare. This not only safeguards the individual health and dignity of newcomers but also nurtures the resilience and prosperity of our society as a whole. Ensuring equitable healthcare means acknowledging that immigrants may have distinct needs due to cultural and linguistic barriers or other social determinants of health. They may also be...

Read more
 

Point-of-care RNA testing: Can it close the gap in hepatitis C diagnosis?

 April 22, 2024 •  By Tamara Barnett

Hepatitis C is a viral infection that can cause liver damage and scarring and make a person very sick if left untreated. Nearly one-quarter of people who have ever had hepatitis C in Canada are unaware of their status, so increasing testing remains pivotal if Canada is to eliminate hepatitis C as a public health threat by 2030. Many advances have been made over the past few years, and more tools are available than ever to test people for hepatitis C. Point-of-care RNA testing for hepatitis C is of particular interest to many service providers because it can be conducted outside...

Read more
 

Tackling misconceptions: Hepatitis C treatment for people who use drugs

 April 22, 2024 •  By Romane Close

With the advent of treatments called direct-acting antivirals (DAAs), a huge number of people across Canada have been successfully cured of hepatitis C. However, efforts to cure some of the most affected communities continue to be hindered by incorrect or outdated information. For example, many successes in curing hepatitis C have been achieved through the determination of people who use drugs, and yet they still encounter access barriers due to discrimination and problematic misconceptions around treatment eligibility. These gaps in knowledge can be addressed by raising awareness about hepatitis C treatment and organizations across Canada have been working to clarify...

Read more
 

Busting common myths about hepatitis C treatment in Canada

 March 19, 2024 •  By Sofia Bartlett

Highly effective medications that can cure hepatitis C infection, called direct-acting antivirals (DAAs), have been approved for use in Canada for people over the age of 18 since 2014. These medications are well-tolerated, nearly 100% effective, and have treatment durations of just eight or 12 weeks. DAAs have simplified hepatitis C treatment considerably, allowing treatments to be prescribed by primary care providers, such as nurse practitioners and family doctors. Now that the treatment itself is so simple, getting coverage for reimbursement of DAAs is the most complicated and challenging aspect of treating hepatitis C infection in Canada. Almost 90% of...

Read more
 

A conversation between Dr. Theresa Tam and Jade Elektra

 February 29, 2024 •  By Dr. Theresa Tam and Jade Elektra

Undetectable = Untransmittable (U=U) refers to the scientific consensus that HIV cannot be sexually transmitted when a person living with HIV consistently takes antiretroviral therapy (ART) and the amount of HIV in their blood remains very low—so low that it cannot be detected by many standard HIV tests. While the U=U message empowers people living with HIV and reduces stigma associated with the virus, it is only effective if individuals living with HIV are able to continuously take their medication. Some people in Canada, such as African, Caribbean and Black communities, Indigenous people, gay, bisexual, and other men who have...

Read more